Nancy Andrews - Novartis Non-Executive Independent Director

<div class='circular--portrait' style='background:#347AFC;color: #ffffff;font-size:4em;padding-top: 25px;;'>NO</div>
NVS -- USA Stock  

Report: 21st of July 2020  

  Director
Dr. Nancy C. Andrews, M.D., Ph.D., was NonExecutive Independent Director of Novartis Inc. since February 27, 2015. She is a Member of the Research Development Committee and the Risk Committee. Dr. Andrews is dean emerita of the Duke University School of Medicine and vice chancellor emerita for academic affairs at Duke University in the United States. She served as dean and vice chancellor from 2007 to 2017. She is a professor of pediatrics, pharmacology and cancer biology at Duke, and was elected as a fellow of the American Association for the Advancement of Science and to membership in the US National Academy of Sciences, the National Academy of Medicine, and the American Academy of Arts and Sciences. She is chair of the board of directors of the American Academy of Arts and Sciences and of the Burroughs Wellcome Fund, a member of the Massachusetts Institute of Technology Corporationrationration, and former president of the American Society for Clinical Investigation. Additionally, she serves on the council of the National Academy of Medicine and on the Scientific Management Review Board of the US National Institutes of Health
Age: 61  Director Since 2015  Ph.D    
41 61 324 1111  http://www.novartis.com
Andrews holds a doctorate in biology from MIT and a doctor of medicine from Harvard Medical School. She completed her residency and fellowship trainings in pediatrics and hematology/oncology at Boston Children?s Hospital and the DanaFarber Cancer Institute, also in the US, and served as an attending physician at Boston Children?s Hospital. Prior to joining Duke, Dr. Andrews was director of the Harvard/MIT M.D.Ph.D. Program, and dean of basic sciences and graduate studies as well as professor of pediatrics at Harvard Medical School. From 1993 to 2006, she was a biomedical research investigator at the Howard Hughes Medical Institute in the US. Her research expertise is in iron homeostasis and mouse models of human diseases.

Nancy Andrews Latest Insider Activity

Novartis Management Efficiency

Novartis AG has Return on Asset of 5.93 % which means that on every $100 spent on asset, it made $5.93 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 15.16 %, implying that it generated $15.16 on every 100 dollars invested. Novartis management efficiency ratios could be used to measure of how well the company is managing its routine affairs as well as how well it utilizes its assets and manages liabilities. Novartis Return on Average Equity is relatively stable at the moment as compared to the past year. Novartis reported last year Return on Average Equity of 0.17. As of 07/14/2020, Return on Invested Capital is likely to grow to 0.26, while Return on Average Assets are likely to drop 0.08. Novartis Average Assets are relatively stable at the moment as compared to the past year. Novartis reported last year Average Assets of 131.97 Billion. As of 07/14/2020, Tangible Asset Value is likely to grow to about 71.6 B, while Return on Average Assets are likely to drop 0.08. As of 07/14/2020, Total Liabilities is likely to grow to about 64.8 B. Also, Current Liabilities is likely to grow to about 29.2 B
The company has 36.69 B in debt with debt to equity (D/E) ratio of 0.72, which is OK given its current industry classification. Novartis AG has a current ratio of 0.73, suggesting that it has not enough short term capital to pay financial commitments when the payables are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Tony MokAstrazeneca PLC
2019
Thomas GlanzmannGrifols S A
2017
Rochelle LazarusMerck Company
2004
Raul AlvarezEli Lilly And
2009
Dinesh PaliwalBristol Myers Squibb
2013
Etienne DavignonGilead Sciences
N/A
Ian DavisJohnson Johnson
2010
Eugene WashingtonJohnson Johnson
2012
Carolyn BertozziEli Lilly And
2017
Anna LluchGrifols S A
2008
Thomas GlocerMerck Company
2007
Katherine BaickerEli Lilly And
2011
John CoganGilead Sciences
2013
Vicki SatoBristol Myers Squibb
2017
Shriti VaderaAstrazeneca PLC
2011
Urs RohnerGlaxoSmithKline PLC
2015
Deryck MaughanGlaxoSmithKline PLC
2013
Paul RothmanMerck Company
2015
John NoseworthyMerck Company
2017
Peter WendellMerck Company
2003
Genevieve BergerAstrazeneca PLC
2012

Company Summary

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company was founded in 1895 and is headquartered in Basel, Switzerland. Novartis operates under Drug ManufacturersGeneral classification in the United States and is traded on BATS Exchange. It employs 109000 people.Novartis AG (NVS) is traded on BATS Exchange in USA. It is located in Lichtstrasse 35 and employs 109,000 people. Novartis AG was previously known as NOVARTIS AG and was traded on BATS Exchange under the symbol NVSEF. Novartis is listed under Pharmaceutical Products category by Fama And French industry classification.

Novartis AG Leadership Team

Ton Buechner, Non-Executive Independent Director
Verena Briner, Non-Executive Independent Member of the Board
Chris Ilsley, President CEO
Steven Baert, Chief People & Organization Officer, Member of the Executive Committee
Richard Saynor, Chief Executive Officer of Sandoz, Member of the Executive Committee
Richard Francis, Member of the Executive Committee and Division Head, Sandoz
Daniel Vasella, Honorary Chairman of the Board
Pierre Landolt, Member of the Board of Directors
Elizabeth Doherty, Non-Executive Independent Director
Erwin Vanhaecke, Head Novartis Group Quality
Elizabeth Barrett, CEO, Novartis Oncology
Mark Fishman, Member of the Executive Committee and President of Novartis Institute for BioMedical Research (NIBR)
Charlotte PamerWieser, Corporate Secretary
Shannon Klinger, Chief Risk and Compliance Officer, Group General Counsel
Samir Shah, Global Head Investor Relations
David Epstein, Member of the Executive Committee, Division Head, Pharmaceuticals
Srikant Datar, Non-Executive Independent Director
MarieFrance Tschudin, President of Novartis Pharmaceuticals, Member of the Executive Committee
Simon Moroney, Director
Francesco Balestrieri, Chief Executive Officer of Sandoz, Member of the Executive Committee
Steffen Lang, Global Head of Novartis Technical Operations, Member of the Executive Committee
Joerg Reinhardt, Independent Non-Executive Chairman of the Board
Paul Hudson, Chief Executive Officer of Novartis Pharmaceuticals, Member of the Executive Committee
Brian McNamara, Member of the Management Board, Division Head, Novartis OTC
Andrews C, Non-Executive Independent Director
Michele Galen, Head Communications
Charles Sawyers, Non-Executive Independent Member of the Board
John Tsai, Head of Global Drug Development and Chief Medical Office, Member of the Executive Committee
Dimitri Azar, Non-Executive Independent Director
Frans Houten, Non-Executive Independent Director
Nancy Andrews, Non-Executive Independent Director
Susanne Schaffert, CEO Novartis Oncology, Member of the Executive Committee
Enrico Vanni, Independent Non-Executive Vice Chairman of the Board
Bertrand Bodson, Chief Digital Officer, Member of the Executive Committee
Robert Weltevreden, Head of Novartis Business Services (NBS), Member of the Executive Committee
Andre Wyss, Member of the Executive Committee, Novartis Business Services and Country President for Switzerland
Bruno Strigini, CEO of Novartis Oncology, Member of the Executive Committee
Vasant Narasimhan, Global Head of Drug Development and Chief Medical Officer for Novartis, Member of the Executive Committee
Alex Krauer, Honorary Chairman of the Board
Michael Ball, CEO of Alcon, Member of the Executive Committee
Jeffrey George, Member of the Executive Committee and Division Head, Sandoz
Patrice Bula, Non-Executive Independent Director
Peter Kornicker, Chief Compliance Officer
Andreas Planta, Non-Executive Independent Director
Joseph Jimenez, CEO, Member of the Executive Committee
Ulrich Lehner, Vice Chairman of the Board of Directors, Non-Executive Director
William Winters, Non-Executive Independent Member of the Board
Ann Fudge, Non-Executive Independent Director
George Gunn, Member of the Executive Committee, Division Head, Novartis Animal Health of Head, Corporate Responsibility
Paul Arkel, Head of Corporate Strategy and External Affairs
James Bradner, President of the Novartis Institutes for BioMedical Research (NIBR), Member of the Executive Committee
Klaus Moosmayer, Chief Ethics, Risk and Compliance Officer, Member of the Executive Committee
Felix Ehrat, General Counsel and General Counsel of Novartis International Ag
Harry Kirsch, Chief Financial Officer, Member of the Executive Committee
Andrin Oswald, Member of the Executive Committee, Division Head, Vaccines and Diagnostics
Bridgette Heller, Director

Stock Performance Indicators

Did you try this?

Run Idea Breakdown Now

   

Idea Breakdown

Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
All  Next Launch Module

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see Stocks Correlation. Please also try Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page